MARLBOROUGH, Mass.,
Sept. 18, 2019 /PRNewswire/ -- Boston
Scientific Corporation (NYSE: BSX) today announced key data that
will be presented at the 31st Transcatheter Cardiovascular
Therapeutics (TCT), the annual scientific symposium of the
Cardiovascular Research Foundation, in San Francisco, on September 25 - September 29.
Notably, data from the EVOLVE Short DAPT study evaluating the
safety of early dual antiplatelet therapy discontinuation in a
large number of patients with high bleeding risk treated with the
SYNERGY™ Bioabsorbable Polymer (BP) Stent will be featured during a
late-breaking science session on Thursday,
September 26.
"We look forward to the presentation of late-breaking data on
our SYNERGY stent and the important discussions these data will
warrant around the advancement of therapies to treat coronary
artery disease," said Dr. Ian Meredith,
AM., executive vice president and global chief medical
officer, Boston Scientific. "We also will celebrate the milestone
of 100,000 patient implants of the WATCHMAN™ Left Atrial Appendage
Closure Device worldwide, and anticipate new clinical data across
our Interventional Cardiology portfolio further supporting
physicians as they determine the most appropriate treatment
strategies for patients with cardiovascular disease."
ABSTRACTS OF INTEREST (listed chronologically)
Wednesday, September 25
- LOTUS™ Aortic Valve System: Mid-term Outcomes after
Transcatheter Aortic Valve Replacement with a Mechanically-expanded
versus Self-Expandable Valve: 3-year Results from the REPRISE III
Randomized Trial: David Rizik, M.D.,
will present at 3:45 p.m. in Room
209-210.
Thursday, September 26
- SYNERGY BP Stent: (Late-Breaking Science) Primary
Outcomes of the EVOLVE Short DAPT Study Evaluating 3-Month Dual
Antiplatelet Therapy in High Bleeding Risk Patients Treated With
the SYNERGY Everolimus-Eluting, Bioabsorbable Polymer-Coated
Coronary Stent: Dr. Ajay Kirtane
will present during the Late-Breaking Science session at
12:15 p.m. in Main Arena 1.
- LOTUS Aortic Valve System: Budget Impact of Mechanically
Expanded Versus Self-expanding Transcatheter Aortic Valve
Replacement in High-risk Patients with Aortic Stenosis: A Medicare
Perspective: A poster developed by David
Rizik, M.D. will be available for viewing from
9:15-10:45 a.m. in Moscone South,
Hall D, Exhibition Level.
Friday, September 27
- PLATINUM Diversity: Clinical Impact of DAPT Cessation
Within 12 Months of Drug-eluting Stent Implantation in Caucasians
and Minorities: Insights From the PLATINUM Diversity and PROMUS
Element Plus Post-Approval Study: Dr. Davide Cao will present at 9:30 a.m. in Moderated Posters 4, Exhibit Hall,
Exhibition Level.
- WATCHMAN Left Atrial Appendage Closure
Device: Budget Implications of Atrial Fibrillation Stroke
Risk Reduction Strategies to Medicare and Medicare Beneficiaries:
An Analysis of Pooled, Long-term Trial Data: Dr. Vivek Reddy, M.D., will present at 3:50 p.m. in the Moderated Posters 2, Exhibit
Hall, Exhibition Level.
Saturday, September 28
- PLATINUM Diversity: Clinical Outcomes in Women and
Minorities According to the Urgency of Percutaneous Coronary
Intervention: Dr. Davide Cao will
present at 9:30 a.m. in Moderated
Posters 8, Exhibit Hall, Exhibition Level.
All presentations are listed in Pacific Time and will take place
at the Moscone Center. For more information, visit Boston
Scientific at booth #1534 or follow @BSCCardiology.
The company will also host an investor event and webcast on
Friday, September 27 from 12:00 – 1:00
p.m. PT to provide a business update and answer questions
from investors about the Boston Scientific cardiovascular
portfolio. The event will be accessible at
www.bostonscientific.com/investors. A replay of the webcast will be
accessible at www.bostonscientific.com/investors beginning
approximately one hour following the completion of the event.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology leader
for 40 years, we advance science for life by providing a broad
range of high performance solutions that address unmet patient
needs and reduce the cost of healthcare. For more information,
visit www.bostonscientific.com and connect on Twitter and
Facebook.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Forward-looking statements may be identified by words
like "anticipate," "expect," "project," "believe," "plan,"
"estimate," "intend" and similar words. These forward-looking
statements are based on our beliefs, assumptions and estimates
using information available to us at the time and are not intended
to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding clinical outcomes, product launches, and product
performance and impact. If our underlying assumptions turn out to
be incorrect, or if certain risks or uncertainties materialize,
actual results could vary materially from the expectations and
projections expressed or implied by our forward-looking statements.
These factors, in some cases, have affected and in the future
(together with other factors) could affect our ability to implement
our business strategy and may cause actual results to differ
materially from those contemplated by the statements expressed in
this press release. As a result, readers are cautioned not to place
undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; the
closing and integration of acquisitions; intellectual property;
litigation; financial market conditions; and future business
decisions made by us and our competitors. All of these factors are
difficult or impossible to predict accurately and many of them are
beyond our control. For a further list and description of these and
other important risks and uncertainties that may affect our future
operations, see Part I, Item 1A – Risk Factors in our most recent
Annual Report on Form 10-K filed with the Securities and Exchange
Commission, which we may update in Part II, Item 1A – Risk Factors
in Quarterly Reports on Form 10-Q we have filed or will file
hereafter. We disclaim any intention or obligation to publicly
update or revise any forward-looking statements to reflect any
change in our expectations or in events, conditions or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary
statement is applicable to all forward-looking statements contained
in this document.
CONTACT:
Angela Mineo
Communications Manager
(763) 955-8325 (office)
Angela.Mineo@bsci.com
Susie Lisa, CFA
Investor Relations
Boston Scientific Corporation
(508) 683-5565 (office)
BSXInvestorRelations@bsci.com
View original
content:http://www.prnewswire.com/news-releases/boston-scientific-announces-scheduled-presentations-at-transcatheter-cardiovascular-therapeutics-2019-300920332.html
SOURCE Boston Scientific Corporation